Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma

Main Article Content

Danny Rischin
Michael R Migden
Anne Lynn S Chang
Et al.

Keywords

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi.

 

Copyright 2018 SKIN